Clinical trial · Observational
Gastric Cancer Liver Metastasis Cohort of China
Retrospective Multi-institutional Cohort Study of Gastric Cancer Liver Metastasis in Real-world Data of China
NCT04574245CI-TRIAL-00061244RECORDunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multi-institutional retrospective cohort study aimed to describe and analyze the overall clinical characteristics, therapeutic status and prognosis pattern of gastric cancer liver metastasis (GCLM) in China.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm Metastasis | — | UNRESOLVED | — |
| Stomach Neoplasms | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gastrectomy; Hepatectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Resectable group
- interventionNames
- Procedure: Gastrectomy; Hepatectomy
- label
- Potentially resectable group
- label
- Unresectable group
Primary outcomes (3)
- measure
- 1-year overall survival
- timeFrame
- 2011/01/01-2020/12/31
- description
- The proportion (%) of gastric cancer liver metastasis patients that survived beyond one-year follow-up period.
- measure
- 3-year overall survival
- timeFrame
- 2011/01/01-2021/12/31
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Gastric cancer liver metastases cases aged over 18 years old; * Primary gastric carcinoma (including different histopathological types) confirmed by biopsy or surgery (pre-, intra- or post- treatment); * In hospital cases between 2020/01/01 to 2019/12/3. Exclusion Criteria: * Poor compliance to treatment or lost to follow-up; * Gross loss of clinical data.
References
Publications (1)
- BACKGROUNDZhang K, Chen L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases. Ther Adv Med Oncol. 2020 Feb 20;12:1758835920904803. doi: 10.1177/1758835920904803. eCollection 2020. PMID 32127925